VERVE THERAPEUTICS INC. - COMMON STOCK

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

14 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

11 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

24 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

27 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

29 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

13 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

29 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

05 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 15:26:49 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results

08 Aug 2024 06:00:01 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

28 Jun 2024 06:00:00 By Nasdaq GlobeNewswire